肿瘤疫苗及其他。
Tumor vaccines and beyond.
机构信息
Stem Cell Allogeneic Transplant Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Cytotherapy. 2011 Jan;13(1):8-18. doi: 10.3109/14653249.2010.530649. Epub 2010 Nov 10.
Abstract
For the last two decades the immunotherapy of patients with solid and hematopoietic tumors has met with variable success. We have reviewed the field of tumor vaccines to examine what has worked and what has not, why this has been the case, how the anti-tumor responses were examined, and how we can make tumor immunity successful for the majority of individuals rather than for the exceptional patients who currently show successful immune responses against their tumors.
摘要
在过去的二十年中，实体瘤和血液系统肿瘤患者的免疫治疗取得了不同程度的成功。我们回顾了肿瘤疫苗领域，以探讨哪些方法有效，哪些方法无效，为什么会出现这种情况，如何检查抗肿瘤反应，以及如何使大多数人而非目前对肿瘤有成功免疫反应的少数例外患者获得肿瘤免疫成功。
相似文献
1
Tumor vaccines and beyond.
Cytotherapy. 2011 Jan;13(1):8-18. doi: 10.3109/14653249.2010.530649. Epub 2010 Nov 10.
2
Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Cancer J. 2004 Jan-Feb;10(1):1-7. doi: 10.1097/00130404-200401000-00001.
3
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Theranostics. 2020 May 15;10(13):6011-6023. doi: 10.7150/thno.38742. eCollection 2020.
4
Specificity in cancer immunotherapy.
Semin Immunol. 2008 Oct;20(5):276-85. doi: 10.1016/j.smim.2008.07.001. Epub 2008 Aug 5.
5
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. eCollection 2018.
6
The identification of cancer antigens: impact on the development of cancer vaccines.
Cancer J. 2000 Apr;6 Suppl 2:S142-9.
7
Harnessing neoantigen specific CD4 T cells for cancer immunotherapy.
J Leukoc Biol. 2020 Apr;107(4):625-633. doi: 10.1002/JLB.5RI0220-603RR. Epub 2020 Mar 14.
8
Immunotherapy of cancer through targeting of minor histocompatibility antigens.
Curr Opin Immunol. 2005 Apr;17(2):202-10. doi: 10.1016/j.coi.2005.01.010.
9
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004.
10
CD4 T cells and their role in antitumor immune responses.
J Exp Med. 1999 Mar 1;189(5):753-6. doi: 10.1084/jem.189.5.753.
引用本文的文献
1
Current Development of Therapeutic Vaccines in Lung Cancer.
Vaccines (Basel). 2025 Feb 14;13(2):185. doi: 10.3390/vaccines13020185.
2
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.
Signal Transduct Target Ther. 2022 Sep 19;7(1):331. doi: 10.1038/s41392-022-01136-2.
3
Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Hum Vaccin Immunother. 2015;11(4):851-69. doi: 10.1080/21645515.2015.1009814.
4
Expression of the brother of the regulator of imprinted sites gene in the sputum of patients with lung cancer.
Korean J Thorac Cardiovasc Surg. 2014 Aug;47(4):378-83. doi: 10.5090/kjtcs.2014.47.4.378. Epub 2014 Aug 5.
5
Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.
Immunology. 2014 Sep;143(1):96-108. doi: 10.1111/imm.12292.
6
Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity.
J Immunother. 2013 Jan;36(1):41-51. doi: 10.1097/CJI.0b013e318274590e.
本文引用的文献
1
Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996. 274: 94-96.
J Immunol. 2011 Jul 1;187(1):7-9.
2
Minor histocompatibility antigen discovery: turning up the HEATR.
Blood. 2010 Jun 10;115(23):4630-1. doi: 10.1182/blood-2010-03-274282.
3
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.
4
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.
Cell Mol Immunol. 2010 Sep;7(5):389-95. doi: 10.1038/cmi.2010.28. Epub 2010 May 31.
5
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Cancer Res. 2010 Jun 1;70(11):4335-45. doi: 10.1158/0008-5472.CAN-09-3767. Epub 2010 May 18.
6
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.
7
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80. doi: 10.1073/pnas.1003345107. Epub 2010 Apr 12.
8
Targeting immune suppressing myeloid-derived suppressor cells in oncology.
Crit Rev Oncol Hematol. 2011 Jan;77(1):12-9. doi: 10.1016/j.critrevonc.2010.02.004. Epub 2010 Mar 20.
9
Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.
Blood. 2010 Jun 10;115(23):4923-33. doi: 10.1182/blood-2009-12-260539. Epub 2010 Mar 4.
10
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Cancer. 2010 Apr 1;116(7):1757-66. doi: 10.1002/cncr.24899.
Zotero 插件